Edition:
India

AnaptysBio Inc (ANAB.OQ)

ANAB.OQ on NASDAQ Stock Exchange Global Select Market

41.21USD
20 Sep 2019
Change (% chg)

$-0.54 (-1.29%)
Prev Close
$41.75
Open
$41.05
Day's High
$42.25
Day's Low
$40.70
Volume
321,483
Avg. Vol
106,882
52-wk High
$110.00
52-wk Low
$38.59

Latest Key Developments (Source: Significant Developments)

AnaptysBio Inc Says CFO Dominic Piscitelli To Resign, Effective As Of September 9
Tuesday, 20 Aug 2019 

Aug 19 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO INC - CFO DOMINIC PISCITELLI TO RESIGN, EFFECTIVE AS OF SEPTEMBER 9.ANAPTYSBIO INC - APPOINTED ERIC LOUMEAU AS INTERIM CHIEF FINANCIAL OFFICER AND GENERAL COUNSEL.  Full Article

Anaptysbio Q2 Loss Per Share $0.89
Friday, 9 Aug 2019 

Aug 8 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES.Q2 LOSS PER SHARE $0.89.Q2 EARNINGS PER SHARE ESTIMATE $-0.99 -- REFINITIV IBES DATA.EXPECTS THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND ITS CURRENT OPERATING PLAN AT LEAST THROUGH END OF 2020.  Full Article

AnaptysBio Presents Updated Data From Etokimab Phase 2a Proof-Of-Concept Clinical Trial In Severe Eosinophilic Asthma
Wednesday, 5 Jun 2019 

June 5 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO PRESENTS UPDATED DATA FROM ETOKIMAB PHASE 2A PROOF-OF-CONCEPT CLINICAL TRIAL IN SEVERE EOSINOPHILIC ASTHMA.ANAPTYSBIO INC - ETOKIMAB WAS WELL TOLERATED AND NO SERIOUS ADVERSE EVENTS WERE REPORTED.ANAPTYSBIO INC - PLANS TO INITIATE A PHASE 2B TRIAL IN EOSINOPHILIC ASTHMA PATIENTS IN 2019.ANAPTYSBIO INC - ETOKIMAB WAS GENERALLY WELL TOLERATED IN ALL PATIENTS AND NO SERIOUS ADVERSE EVENTS WERE REPORTED.  Full Article

Anaptysbio Announces Third Quarter 2018 Financial Results
Friday, 9 Nov 2018 

Nov 8 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES.ANAPTYSBIO INC QTRLY LOSS PER SHARE $0.66.ANAPTYSBIO INC QTRLY COLLABORATION REVENUE WAS $5.0 MILLION FOR 3 MONTHS ENDED SEPT 30, 201 COMPARED TO NO REVENUE FOR 3 MONTHS ENDED SEPT 30, 2017.ANAPTYSBIO INC - EXPECTS THAT CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND CURRENT OPERATING PLAN AT LEAST THROUGH END OF 2020.ANAPTYSBIO INC - ANTICIPATES TOP-LINE DATA FROM ECLIPSE TRIAL WILL BE AVAILABLE IN H2 OF 2019.  Full Article

AnaptysBio Reports Qtrly Loss Per Share $0.57
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES.ANAPTYSBIO INC QTRLY LOSS PER SHARE $0.57.ANAPTYSBIO - EXPECTS CASH, CASH EQUIVALENTS & INVESTMENTS TO FUND CURRENT OPERATING PLAN THROUGH END OF 2019.ANAPTYSBIO - CASH, CASH EQUIVALENTS & INVESTMENTS TOTALED $300.6 MILLION AS OF JUNE 30, 2018 VERSUS $324.3 MILLION AS OF DEC 31, 2017.  Full Article

AnaptysBio Qtrly ‍Loss Per Share $0.30
Tuesday, 6 Mar 2018 

March 5 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND 2018 PIPELINE MILESTONES.Q4 REVENUE $3.0 MILLION.QTRLY ‍LOSS PER SHARE $0.30.‍EXPECTS THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND ITS CURRENT OPERATING PLAN THROUGH END OF 2019​.  Full Article

Anaptysbio qtrly loss per share $0.45‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Anaptysbio Inc ::Anaptysbio announces third quarter 2017 financial results and provides pipeline updates.Qtrly loss per share $0.45‍​.Q3 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Anaptysbio Inc :Anaptysbio reports positive anb019 top-line phase 1 clinical trial results.Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties in study​.ANB019 was well-tolerated by all subjects and no dose-limiting toxicities were observed to date in study​.Plans to initiate phase 2 clinical trials of ANB019 in generalized pustular psoriasis, palmo-plantar pustular psoriasis patients in 2018​.  Full Article

Cormorant Asset Management reports 5.02 pct passive stake in Anaptysbio as of Oct. 19 ‍​
Saturday, 21 Oct 2017 

Oct 20 (Reuters) - Cormorant Asset Management LLC: :Cormorant Asset Management, LLC reports 5.02 percent passive stake in Anaptysbio Inc as of October 19 - SEC filing ‍​.  Full Article

AnaptysBio prices public offering of 3 mln shares at $68.50 per share
Friday, 13 Oct 2017 

Oct 12 (Reuters) - AnaptysBio Inc -:AnaptysBio announces pricing of public offering.Says public offering of 3.00 million common shares priced at $68.50per share.  Full Article